Six clues. One hidden briefcase. A community adventure returns. ARCHBOLD, Ohio, June 12, 2026 (GLOBE NEWSWIRE) — F&M Bank (“F&M”), an Archbold, Ohio-based bank owned by Farmers & Merchants Bancorp, Inc. (Nasdaq: FMAO), is bringing back one of summer’s most anticipated community adventures: The Great Briefcase Hunt. Beginning June 15, the community across the F&M footprint will once again have the chance to follow weekly clues in search of a hidden briefcase worth $10,000 – with $5,000 awarded to the winner and $5,000 donated to a local charity from an approved F&M charity list. After generating excitement across communities in 2025, The Great Briefcase Hunt returns bigger, bolder, and ready to spark another summer of mystery, teamwork, and adventure. Participants will work together to solve six clues that...

The new VENTANA PTEN (SP218) RxDx Assay fulfils an unmet medical need by helping clinicians identify patients with PTEN protein loss who may benefit from combination treatment with TRUQAP In prostate cancer, PTEN protein loss is associated with faster disease progression and reduced benefit from current standard-of-care treatments1 The FDA approval reinforces Roche’s leadership in companion diagnostics and its ongoing commitment to expanding personalised healthcare to improve patient outcomesBasel, 12 June 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the VENTANAⓇ PTEN (SP218) RxDx Assay is the first immunohistochemistry (IHC) companion diagnostic test to receive U.S. Food and Drug Administration (FDA) approval for determining PTEN protein loss, also known as PTEN deficiency, in tumours of patients with prostate...

Wuxi, China, June 12, 2026 (GLOBE NEWSWIRE) — Park Ha Biological Technology Co., Ltd., (NASDAQ: BYAH) an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), today announced that it has entered into a securities purchase agreement with several investors for the sales of the Company’s securities in a registered direct offering (the “Offering”) consisting of up to 1,133,332 of the Company’s Class A ordinary shares, par value $0.001 each (the “Shares”), and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 200,000 Class A ordinary shares (the “Warrant Shares”), at a combined purchase price of $1.50 per Share and Pre-Funded Warrant. The gross proceeds to the Company from this Offering are expected to be approximately $2.0 million. The Offering is expected to close...

Post-combination company, SL Science Holding Limited, to commence trading on the Nasdaq Stock Market under the ticker symbol “SLBT” Transaction provides strategic capital to advance proprietary Gamma delta T cell-based “off-the-shelf” cellular therapies for solid tumor indications, including pancreatic and brain cancers Leadership team bolstered by seasoned executives and highly experienced independent directors to drive the next phase of clinical and commercial growthTAIPEI, Taiwan, June 12, 2026 (GLOBE NEWSWIRE) — SL BIO Ltd. (“SL Bio” or the “Company”), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced the closing of its previously announced business combination with Horizon Space Acquisition II Corp. (Nasdaq: HSPT) (“Horizon Space”), a...

NEW HAVEN, Conn., June 12, 2026 (GLOBE NEWSWIRE) — Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately. Votes must be received by 11:59 p.m., Eastern Time, on June 14, 2026, to be voted at the Annual Meeting. In order to ensure that there is a quorum required for the shareholders’ meeting that is scheduled to take place tomorrow, June 15, 2026, at 10 a.m. Eastern Time. At the time of this press release, approximately 42% of shares have been voted. For the company to hold the shareholder meeting, a minimum of 50% of shares must be voted. If the Company does not receive sufficient votes to establish a quorum, it may need to adjourn and reconvene the shareholder meeting, which would result in high additional costs....

Leo International Precision Health AG Announces Results of the 2026 Annual General Meeting Planegg / Martinsried, Germany, June 12, 2026 – Leo International Precision Health AG (“LIPH” or the “Company”, ticker symbol: LEOW), a holding company building a global integrated AI-driven healthcare ecosystem, today held its Annual General Meeting (AGM) as an in-person event. During the AGM, the Management Board reported on the Company’s development in fiscal year 2025 as well as the current business performance and strategic objectives for the ongoing fiscal year. Key topics included the establishment of the integrated precision health portfolio, the successful contribution of the first six portfolio companies, and the planned further expansion through additional acquisitions in Europe and Asia. The Management and Supervisory Board answered all...

GREELEY, Colo., June 12, 2026 (GLOBE NEWSWIRE) — Pilgrim’s today announced a strategic investment to expand and modernize its Ellijay, Georgia poultry facility, strengthening the company’s ability to meet evolving consumer preferences, support key customer growth, and enhance long-term operational excellence. The approximately $75 million investment will increase harvesting and portioning capacity in Ellijay and enable the facility to produce a broader mix of higher-value, boneless chicken products — including those used in popular chicken sandwiches, tenders, and other fast-growing categories. This investment supports key customers’ growth plans, through a change in Pilgrim’s portfolio mix in Ellijay. “As consumer demand shifts and our customers grow, we are investing to ensure our operations are positioned for the future,” said...

PRESS RELEASE Arcueil, June 12, 2026 2026 half-year financial report release Aramis Group today announces that the company has filed its 2026 half-year financial report, ended March 31, 2026, with the French Financial Markets Authority (Autorité des marchés financiers). Aramis Group 2026 half-year financial report is available on the Company’s website www.aramis.group under “Investors / Regulated information”. *** About Aramis Group – www.aramis.group Aramis Group is the European leader for B2C online used car sales and operates in six countries. A fast-growing group, an e-commerce expert and a vehicle refurbishing pioneer, Aramis Group takes action each day for more sustainable mobility with an offering that is part of the circular economy. Founded in 2001, it has been revolutionizing its market for 25 years, focused on ensuring the satisfaction...

MELBOURNE, Australia, June 12, 2026 (GLOBE NEWSWIRE) — Gelteq Limited (“Gelteq” or the “Company”) today announced the successful completion of its veterinary palatability trials conducted in collaboration with Kemin Industries (“Kemin”), a leading U.S.-based global ingredient manufacturer. The trials were designed to optimise flavour profiles and assess canine acceptance of products powered by Gelteq® technology, the Company’s proprietary gel-based delivery platform. Gelteq tested a variety of products, including a range deliberately formulated with natural bitter compounds that canines would ordinarily reject. The results demonstrated strong canine acceptance across the flavour profiles and confirmed the ability of Gelteq® technology to effectively mask bitter flavour profiles while improving palatability, providing an important...

More than 100 patients treated with ronde-cel in 2L and 3L+ LBCL, with a manufacturing success rate of 97% No Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS, supporting outpatient administration Translational data support biological basis for durable responses, including enhanced memory potential of cytotoxic effector cells from CD62L+ enrichment, and CD19/CD20 dual-targeting to overcome low antigen expression PiNACLE pivotal clinical trial in 3L+ setting data update expected in second half of 2026; pivotal data readout expected in mid-2027, with BLA submission to follow in the second half of 2027SOUTH SAN FRANCISCO, Calif., June 12, 2026 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients...